Gilead Sciences logged a -0.7% change during today's evening session, and is now trading at a price of $80.61 per share. On average, analysts give it a target price of $85.47.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The large-cap company is based in the United States. Gilead Sciences currently returns an annual dividend yield of 3.6%.
Make Sure to Consider the Following Before Buying Gilead Sciences:
Gilead Sciences has moved -0.0% over the last year.
GILD has a forward P/E ratio of 11.8 based on its EPS guidance of 6.82.
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 0.7%.
The company has a price to earnings growth (PEG) ratio of 3.05.
Its Price to Book (P/B) ratio is 4.75
Gilead Sciences Has None
|Date Reported||Cash Flow from Operations ($ k)||Capital expenditures ($ k)||Free Cash Flow ($ k)||YoY Growth (%)|